ArticleScientific reports2026
Role of the ABCG2 transporter in the biodistribution of the food-borne uremic toxin p-cresyl sulfate.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ATP-binding cassette transporter G2 (ABCG2) is a membrane transporter that conditions pharmacokinetics, systemic exposure, and milk secretion of drugs, natural and food-derived compounds, including gut-derived metabolites. p-Cresyl sulfate (pCS), a well-known uremic toxin, is the main metabolite of p-Cresol (pC), produced from dietary aromatic amino acids by gut microbiota. We aimed to characterize the in vitro and in vivo interaction of pCS with the ABCG2 transporter. Using MDCK–II cells overexpressing the transporter, we found that pCS is an in vitro substrate of ABCG2. Furthermore, using wild-type and Abcg2−/− mice, we showed that plasma AUC0−240 min for Abcg2−/− was almost 1.6-fold higher than for wild-type mice. Regarding tissue distribution, the liver, kidney, small intestine, testis, and spleen from Abcg2−/− mice showed significantly higher pCS levels versus the wild-type group. Moreover, pCS accumulation in small intestine content retrieved from wild-type mice was 2-fold higher than in the Abcg2−/− group. Finally, we proved that Abcg2 also affects pCS secretion into milk, with a more than 3-fold higher accumulation in milk and almost 6-fold higher milk-to-plasma ratio of wild-type versus Abcg2−/− mice. Overall, our results disclose that Abcg2 significantly affects plasma levels, biodistribution and milk secretion of pCS, thereby modulating its biological activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.